Liberty Media Exchanges Malone's Series B Stock, Adopts Rights Plan
Liberty Media swapped 2.3 million Series B shares held by John Malone's entities for Series A and Series C shares, adopted a one-year poison pill, and changed Malone's role from Chairman Emeritus to Senior Advisor.
What happened
Liberty Media Corporation, a Nevada-incorporated holding company whose Nasdaq-listed Series A (FWONA) and Series C (FWONK) shares track its businesses, disclosed in a Form 8-K filed Nov. 5, 2026, that on Nov. 4 it entered an Exchange Agreement with John C. Malone, a significant stockholder, and certain related entities (the "Malone Holders").
Under the agreement, the Malone Holders transferred 2,316,537 shares of Series B Common Stock to the company, and Liberty Media issued them 602,302 shares of Series A Common Stock and 5,420,699 shares of Series C Common Stock. The transferred Series B shares were cancelled and retired. Immediately afterward, Liberty Media issued 12,298 additional Series A shares and 63,378 additional Series C shares to a revocable trust of which Malone is sole trustee and beneficiary, in respect of 47,297 Series C shares the trust held that were exchangeable into Series B stock under a prior agreement. Those 47,297 Series C shares remain outstanding.
The Exchange Agreement and related transactions were approved by a special committee of the board made up solely of disinterested and independent directors under Nevada law, advised by its own independent financial and legal advisors. The agreement includes a five-year commitment to provide specified benefits to Malone and, as applicable, his spouse and eligible dependents, indemnification of the Malone Holders for certain losses, and a mutual release of claims arising from the transaction.
Effective immediately after the exchange, Malone ceased to hold the title of Chairman Emeritus, and his employment agreement was amended so that he serves as Senior Advisor. The rest of the employment agreement remains in effect.
Separately, the board declared a dividend of one preferred share purchase right for each outstanding share of Series A, Series B and Series C Common Stock, payable to stockholders of record as of Nov. 16, 2026. Each right entitles the holder to buy one ten-thousandth of a share of Series A Junior Participating Preferred Stock at $426.00, subject to adjustment. The Rights Agreement, dated Nov. 4, 2026, runs with Broadridge Corporate Issuer Solutions as rights agent and expires Nov. 3, 2027 unless redeemed or exchanged earlier.
In the Nov. 5 trading session, FWONA closed at $99.72, up 9.55% from the prior close of $91.03, on volume of 841,700 shares — about 4.5 times its average volume of 187,892, according to the price data.
The share classes, and why the swap matters
Liberty Media has three series of common stock. Series A and Series C trade on Nasdaq under FWONA and FWONK. Series B does not trade publicly; per the filing it carries the company's voting power, while Series A and Series C are the publicly traded series. The filing does not spell out the voting rights of each series beyond describing the Series B shares as the ones the Malone Holders held and the rights plan's definition of an Acquiring Person as someone with 10% or more of voting power (15% for passive institutional investors).
In the exchange, Malone's entities gave up 2,316,537 Series B shares and received 602,302 Series A shares plus 5,420,699 Series C shares — roughly 2.6 Series C shares per Series B share, plus the Series A shares. The trust also received adjustment shares tied to 47,297 exchangeable Series C shares it already held.
The filing describes the exchange and the adjustment share issuance but does not state why the parties agreed to it. It does say the terms were negotiated with an independent special committee.
What this means
An 8-K is the form a US public company files with the SEC to report material events between quarterly reports. This one lists several items at once: entry into and termination of material agreements (1.01, 1.02), unregistered sales of equity (3.02), changes to security holders' rights (3.03), a director or officer change (5.02), amendments to charter or bylaws (5.03), Regulation FD disclosure (7.01) and exhibits (9.01). The filing text provided covers only the Exchange Agreement and the Rights Agreement, so this article does not describe what items 1.02, 3.02, 3.03, 5.02, 5.03, 7.01 or 9.01 contain beyond what those two agreements imply.
The preferred share purchase right is the instrument behind a "rights plan," commonly called a poison pill. It is a dividend of one right per common share. The right is not exercisable at first and trades with the stock. It becomes exercisable — that is, it separates from the shares and gets its own certificate — on the Distribution Date, defined as the earlier of the tenth business day after a public announcement that a person or group has become an "Acquiring Person" (10% or more of voting power, or 15% for a passive institutional investor), or a date the board sets after a tender or exchange offer that would produce such a holder.
Once triggered, the flip-in provision lets each right holder other than the acquiring person buy common stock worth twice the exercise price. The rights plan here has a $426.00 purchase price for one ten-thousandth of a preferred share, a stake the filing says is designed to approximate in value one share of Series A Common Stock. Because of the flip-in, an acquirer who crosses the threshold without board approval faces substantial dilution. The board can redeem the rights for $0.0001 each before anyone becomes an Acquiring Person, or exchange them for common stock after a trigger in some circumstances. The plan expires Nov. 3, 2027.
The filing states the board's stated purpose for the rights plan: to let stockholders "realize the long-term value of their investments by reducing the likelihood that any person or group would gain control of the Company through open market accumulation of shares of Common Stock, or other coercive takeover tactics," and to protect against efforts to use market volatility and macroeconomic conditions to obtain control on terms the board may deem not in stockholders' interests. It also states plainly that the rights may make a merger, tender or exchange offer, or other business combination not approved by the board more difficult or discourage it.
On the exchange: the Series B shares Malone's entities held were cancelled, and the company issued traded Series A and Series C shares in their place plus the trust's adjustment shares. The filing does not disclose Malone's resulting ownership or voting stake, and this article cannot calculate it. The filing also says the exchange, the adjustment share issuance and the termination of the prior exchange agreement took effect immediately, and that Malone's title changed to Senior Advisor at that point.
The stock's 9.55% rise and elevated volume on the day of the filing are facts from the price data. The provided sources do not explain what drove the move.
Sources
- Daily price and volume history
- 8-K filed 2026-11-05
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.